We are proud to announce that GloballuxRx has officially established a daughter company in India:GLOBALLUXRX LABORATORIES PRIVATE LIMITED
What makes this milestone even more special is the timing - this has been achieved just 7 months after our carve-out. A clear sign of how fast, focused, and ambitious the GloballuxRx journey has been from day one.
This step also marks a historic moment for Latvia’s pharmaceutical sector:
GloballuxRx is the first pharma company from Latvia to establish a subsidiary in India.
By directly connecting our EU-based operations with our Indian entity, we are creating a true channel of free trade, benefiting from the EU-India trade agreement and enabling more efficient regulatory, manufacturing, and commercial collaboration.
And this is only the beginning. Our first EU dossier submission - Sacubitril/Valsartan - is planned for the beginning of March, setting the pace for an active and ambitious pipeline rollout with our enhanced formulation of Enzalutimide coming in Q3.
Proud of the team, grateful to our partners, and excited about what’s ahead.
Contact maxim.vlasenko@globalluxrx.comWhat makes this milestone even more special is the timing - this has been achieved just 7 months after our carve-out. A clear sign of how fast, focused, and ambitious the GloballuxRx journey has been from day one.
This step also marks a historic moment for Latvia’s pharmaceutical sector:
GloballuxRx is the first pharma company from Latvia to establish a subsidiary in India.
By directly connecting our EU-based operations with our Indian entity, we are creating a true channel of free trade, benefiting from the EU-India trade agreement and enabling more efficient regulatory, manufacturing, and commercial collaboration.
And this is only the beginning. Our first EU dossier submission - Sacubitril/Valsartan - is planned for the beginning of March, setting the pace for an active and ambitious pipeline rollout with our enhanced formulation of Enzalutimide coming in Q3.
Proud of the team, grateful to our partners, and excited about what’s ahead.
